US warns about risks of Boehringer AIDS drug

	Tweet

U.S. health officials on Wednesday warned the public they had received reports of liver toxicity and deaths related to Boehringer Ingelheim’s AIDS drug, Viramune.

The Food and Drug Administration said doctors should weigh the risks and benefits before prescribing Viramune, which also is known by the generic name nevirapine.

“In spite of the potential for serious and life-threatening liver toxicity and skin rashes with nevirapine, there are multiple reasons why nevirapine remains an important part of an HIV treatment regimen (for many people),” the FDA said in a statement.

The medicine is used in drug cocktails to suppress HIV, the virus that causes AIDS. In many countries, a single dose of the drug is given to pregnant women to prevent mother-to-child transmission of HIV.

Cases of liver damage that produce symptoms such as a rash, fever or other symptoms are more common with Viramune than with other HIV-fighting drugs, the FDA said. Some instances have been fatal.

No serious or fatal liver toxicity has been reported after a single Viramune dose, the FDA said.

Boehringer Ingelheim is a privately held company based in Germany. A company spokeswoman could not immediately be reached for comment. 

RELATED STORIES:
Studies show no extra risk with Pfizer smoking drug   Human tests of anthrax vaccine planned   Drug used worldwide doubles risk of kidney failure   Scientists give more evidence of Vioxx heart risks   COX-2 drugs may suppress immune function-study   More evidence found of painkiller heart risks   Warfarin plus painkiller ups gastric bleeding risk   Spending grows to treat youth behavior   Evidence supports ban on growth promotion use of antibiotics in farming   New Approach Promises Greater Success for Predicting Drug Safety   Strong Drugs without the Addiction   Texas attorney general sues Merck over Vioxx

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]